Modalities

Mission

The PathoQuest mission is to develop proprietary, rapid turn-around-time GMP Next Generation Sequencing (NGS) assays and bioinformatic approaches that are designed to accelerate adventitious agent detection and bioprocess characterization as well as replace animal testing, enabling the safe and high-quality production of biopharmaceuticals.

Modalities

mAbs and Recombinants

Bacterial and mammalian produced proteins, hormones and peptides

READ MORE

Viral Vectors

Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids

READ MORE

Cell Therapies

Including gene modified, or unmodified stem cell therapies, allogeneic or autologous

READ MORE

Vaccines

Inactivated, live-attenuated, recombinant, RNA and viral vector products

READ MORE

RNA

Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing

READ MORE

Cultivated Meat

Engineered cells and tissues cultured in more ethical in vitro environments

READ MORE

When we can help

From pre-clinical development to commercial product. Our biosafety testing and characterization services can help you get your product to patients faster.

DISCOVERY

PRE-CLINICAL

PHASE 1-2

PHASE 3

MARKET

Pre-MCB Testing

MCB/MVSS Testing

In process Control (Bulk Harvest…)

Raw Material Testing / Batch Selection

Investigation in Case of Contamination Suspicion

When we can help

From pre-clinical development to commercial product. Our biosafety testing and characterization services can help you get your product to patients faster.

3Rs

Next generation sequencing is the ethical alternative to in vivo testing for the quality control testing of biologics.

PathoQuest, in partnership with Charles River Laboratories, is the first CRO to conclusively demonstrate the superiority of NGS over conventional in vivo biosafety testing and characterization.

3Rs

Next generation sequencing is the ethical alternative to in vivo testing for the quality control testing of biologics.

PathoQuest, in partnership with Charles River Laboratories, is the first CRO to conclusively demonstrate the superiority of NGS over conventional in vivo biosafety testing and characterization.

Contact us

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

E: contact@pathoquest.com

Sign up for our latest news

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

E: contact@pathoquest.com

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

Sign up for our latest news